Autoimmun Diagnostika

Autoimmun Diagnostika

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.3M

Overview

Autoimmun Diagnostika (AID) is a specialized diagnostics and immunology company with over 30 years of collective experience in EliSpot technology. The company operates as an integrated provider, offering everything from assay components and kits to automated reader systems and CRO services, positioning itself as a one-stop-shop for functional cellular immunology analysis. Its focus on high-sensitivity, single-cell level detection for T and B cell responses caters to vaccine development, autoimmune disease research, and infectious disease monitoring. Based in Straßberg, Germany, AID is a private, revenue-generating entity serving the global research and clinical diagnostics community.

Infectious DiseasesAutoimmune DiseasesOncology

Technology Platform

EliSpot (Enzyme-Linked ImmunoSpot) and FluoroSpot assay platforms for the quantitative, single-cell level detection of functional T-cell and B-cell immune responses through cytokine or antibody secretion. The platform includes specialized automated reader systems for analysis.

Funding History

2
Total raised:$2.3M
Seed$1.5M
Grant$800K

Opportunities

Growing demand for functional immune monitoring driven by vaccine development (especially mRNA), immunotherapy, and personalized medicine.
The ability to offer multiplex FluoroSpot assays and integrated CRO services for clinical trials presents significant expansion potential in both research and diagnostic markets.

Risk Factors

Faces competition from larger diagnostic companies and alternative high-throughput immune monitoring technologies.
Market adoption is dependent on continued preference for the EliSpot methodology within the scientific community.
As a private SME, scaling global operations against well-funded competitors is a challenge.

Competitive Landscape

Competes with other specialized EliSpot providers (e.g., Cellular Technology Limited, Mabtech), large diagnostic companies with broad immunoassay portfolios (e.g., Thermo Fisher, BD, Qiagen), and alternative technologies for cellular functional analysis like flow cytometry and single-cell sequencing. Differentiation is based on deep specialization, integrated systems, and over 30 years of focused expertise.